KR-20260062708-A - OCULAR COMPOSITIONS

Abstract

The present invention provides an ocular composition with improved retention force within the eye, comprising hyaluronic acid nanoparticles having a size of about 1 to 10 nm, wherein the hyaluronic acid nanoparticles are cross-linked between hyaluronic acid molecules to form a network structure.

Inventors

• 이수홍
• 김진수
• 김덕일
• 이민주
• 이건우
• 김시연
• 박철용
• 김한영
• 유지원

Assignees

• 동국대학교 산학협력단
• (주)셀인바이오

Dates

Publication Date

20260507

Application Date

20241029

Claims (6)

1. As an ocular composition with improved retention force within the eye, It comprises hyaluronic acid (HA) nanoparticles having a size of about 1 to 100 nm, and The above hyaluronic acid nanoparticles are, An ocular composition having a network structure formed by cross-linking between hyaluronic acid molecules.
2. In Article 1, The above residual force is, An ocular composition comprising a retention time and amount in the cornea.
3. In Article 2, The retention time of the above ocular composition in the cornea is An ocular composition that is improved by about 60 minutes or more compared to a composition containing hyaluronic acid.
4. In Article 2, The residual amount of the above ocular composition in the cornea is, An ocular composition that is improved by more than 20 times compared to a composition containing hyaluronic acid.
5. In Article 2, 60 minutes after administration, The residual amount of the above ocular composition in the cornea is, An ocular composition that is improved by about 1.5 times or more compared to a composition containing hyaluronic acid.
6. In Article 1, The size of the above hyaluronic acid nanoparticles is, An ocular composition having a length of 3 to 70 nm.

Description

Ocular Compositions The present invention relates to an ocular composition with improved retention within the eye by including hyaluronic acid nanoparticles. Eye drops are liquid medications administered into the eye to protect the eye and to prevent and treat eye diseases. Because eye drops can be easily administered to the eye using a non-invasive method, they are used as a treatment for dry eye syndrome, glaucoma, allergies, and various other eye conditions. On the other hand, eye drops can cause problems regarding tear drainage and loss of the ocular surface barrier; furthermore, they present the inconvenience of requiring regular and consistent repeated application at predetermined times. In other words, the medicinal effect of the substances contained in conventional eye drops may be reduced due to the limitations of contact force on the ocular surface. To overcome these drawbacks, various methods have been proposed to increase viscosity by incorporating specific substances, thereby improving retention on the ocular surface. In particular, hyaluronic acid, a biocompatible material, is the most widely used due to its high water retention and viscosity, which allow it to remain on the ocular surface for a relatively long time. However, conventional hyaluronic acid has a linear bonding structure, which limits its ability to improve adhesion and retention time on the actual ocular surface. The background description of the invention is provided to facilitate a better understanding of the present invention. The matters described in the background description should not be construed as an acknowledgment that they exist as prior art. FIG. 1 is a flowchart of a method for manufacturing an ocular composition according to one embodiment of the present invention. Figure 2 is the result of the particle size distribution of HA nanoparticles of an ocular composition according to one embodiment of the present invention. Figures 3a and 3b show the results of ocular mucosal adhesion according to the size of nanoparticles used in an ocular composition according to one embodiment of the present invention. FIGS. 4a to 4c are ex vivo microscopic images of the corneal surface for an ocular composition according to one embodiment of the present invention and the results of quantification thereof. Figures 5a and 5b are in vivo microscopic images of the surface of a living cornea for an ocular composition according to one embodiment of the present invention and the results of quantification thereof. FIGS. 6a to 6c are in vivo microscopic images of the surface of an excised cornea for an ocular composition according to one embodiment of the present invention and the results of quantification thereof. The advantages and features of the present invention and the methods for achieving them will become clear by referring to the embodiments described below in detail together with the accompanying drawings. However, the present invention is not limited to the embodiments disclosed below but may be implemented in various different forms. These embodiments are provided merely to ensure that the disclosure of the present invention is complete and to fully inform those skilled in the art of the scope of the invention, and the present invention is defined only by the scope of the claims. In this specification, expressions such as “have,” “may have,” “include,” or “may include” indicate the presence of such features (e.g., numerical values, functions, operations, or components such as parts) and do not exclude the presence of additional features. In this specification, expressions such as “A or B,” “at least one of A or/and B,” or “one or more of A or/and B” may include all possible combinations of items listed together. For example, “A or B,” “at least one of A and B,” or “at least one of A or B” may refer to cases including (1) at least one A, (2) at least one B, or (3) both at least one A and at least one B. The expression “configured to” as used in this specification may be replaced, depending on the context, with, for example, “suitable for,” “having the capacity to,” “designed to,” “adapted to,” “made to,” or “capable of.” As used in this specification, the term "or" means "and/or" unless otherwise stated. The term "prevention and treatment of ophthalmic diseases" as used in the present invention refers to the prevention and treatment of corneal and conjunctival epithelial damage caused by endogenous diseases such as Sjögren's syndrome, Stevens-Johnson syndrome, or dry eye syndrome, or exogenous diseases caused by medication after surgery, trauma, or the use of hard contact lenses. The above ophthalmic diseases are not necessarily limited thereto. The term 'pharmaceuticalally acceptable salt' as used in the present invention refers to an acidic or basic salt that may be present in the hyaluronic acid and carboxymethylcellulose of the present invention, unless otherwise indicated. For example, the pharmaceutically acceptable salt inc